Efficacy of tiotropium–olodaterol fixed-dose combination in COPD

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseBethesda (MD)GOLD2016
   Google Scholar
• VestboJEdwardsLDScanlonPDChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
   PubMed Web of Science ®Google Scholar
• LangePCelliBAgustiALung-function trajectories leading to chronic obstructive pulmonary diseaseN Engl J Med2015373211112226154786
   PubMed Web of Science ®Google Scholar
• VestboJLangePNatural history of COPD: focusing on change in FEV1Respirology2016211344326176980
   PubMed Web of Science ®Google Scholar
• MillerARaskinJMThe natural history of COPD: confirming and going beyond Fletcher and PetoEur Respir J201444228028325082904
   PubMed Web of Science ®Google Scholar
• DecramerMJanssensWMiravitllesMChronic obstructive pulmonary diseaseLancet201237998231341135122314182
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEur J Pharmacol201576116817325981302
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• CalverleyPMBurgePSSpencerSAndersonJAJonesPWBronchodilator reversibility testing in chronic obstructive pulmonary diseaseThorax200358865966412885978
   PubMed Web of Science ®Google Scholar
• CooperCBThe connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and functionAm J Med200611910 Suppl 1213116996896
   PubMed Web of Science ®Google Scholar
• TantucciCDuguetASimilowskiTZelterMDerenneJPMilic-EmiliJEffect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patientsEur Respir J19981247998049817148
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• O’DonnellDEVoducNFitzpatrickMWebbKAEffect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary diseaseEur Respir J2004241869415293609
   PubMed Web of Science ®Google Scholar
• DonohueJFCombination therapy for chronic obstructive pulmonary disease: clinical aspectsProc Am Thorac Soc20052427228116267348
   PubMedGoogle Scholar
• GrossNJTiotropium bromideChest200412661946195315596697
   PubMed Web of Science ®Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD009285
   PubMed Web of Science ®Google Scholar
• CasaburiRKukafkaDCooperCBWitekTJJrKestenSImprovement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest2005127380981715764761
   PubMed Web of Science ®Google Scholar
• ChongJKarnerCPoolePTiotropium versus long-acting β-agonists for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD009157
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPMateraMGCazzolaMA systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPDChest201614951181119626923629
   PubMed Web of Science ®Google Scholar
• DhillonSTiotropium/olodaterol: a review in COPDDrugs201676113514626683033
   PubMed Web of Science ®Google Scholar
• MosleyJFSmithLLDuttonBNTiotropium bromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPDP T20164129710226908999
   PubMedGoogle Scholar
• DeeksEDOlodaterol: a review of its use in chronic obstructive pulmonary diseaseDrugs201575666567325773742
   PubMed Web of Science ®Google Scholar
• BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• BeehKMDeromEEchave-SustaetaJThe lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study)Int J Chron Obstruct Pulmon Dis20161119320526893551
   PubMed Web of Science ®Google Scholar
• ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat and tiotropium HandiHaler in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• O’DonnellDCasaburiRDe SousaDEffects of 6 weeks’ treatment with once-daily tiotropium and olodaterol fixed-dose combination on inspiratory capacity and exercise endurance in patients with COPD: The Moracto™ studies [ATS abstract]Am J Respir Crit Care Med2015191A3972
   Web of Science ®Google Scholar
• MaltaisFIturriJBKirstenAMEffects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPDEur Respir J201444Suppl 58238
   Google Scholar
• AalbersRMaleki-YazdiMRHamiltonARandomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the Respimat inhaler in patients with chronic obstructive pulmonary diseaseAdv Ther201532980982226404912
   PubMed Web of Science ®Google Scholar
• BuhlRAbrahamsRGrönkeLVossFFlezarMFergusonGTTiotropium + Olodaterol fixed-dose combination therapy provides lung-function benefits compared with Tiotropium alone in patients with GOLD A/B and C/D chronic obstructive pulmonary disease: post hoc analyses of two 1-year studiesPneumologie201670219
   Google Scholar
• SinghDGagaMSchmidtOEffects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO studiesRespir Res20161717327316465
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGBolitschekJTiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placeboEur Respir J201546Suppl 59PA2958
   Google Scholar
• No authors listedSpiolto Respimat 2.5 microgram/2.5 microgram, inhalation solution (tiotropium and olodaterol)2015 Available from: http://mri.medagencies.org/download/NL_H_3157_001_PARSummary.pdfAccessed October 15, 2016
   Google Scholar
• No authors listedSpiolto Respimat 2.5 microgram/2.5 microgram, inhalation solution [summary of product characteristics]2016 Available from: http://mri.medagencies.org/download/NL_H_3157_001_FinalPI.pdfAccessed October 15, 2016
   Google Scholar
• DeromEFlezarMGrönkeLVossFBuhlREffect of tiotropium + olodaterol therapy on COPD exacerbations in the Tonado studiesAm J Respir Crit Care Med2016193A6805
   Web of Science ®Google Scholar
• FergusonGTFležarMKornSEfficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysisAdv Ther201532652353626112656
   PubMed Web of Science ®Google Scholar
• HalpinDMDahlRHallmannCMuellerATashkinDTiotropium HandiHaler and Respimat in COPD: a pooled safety analysisInt J Chron Obstruct Pulmon Dis20151023925925709423
   PubMed Web of Science ®Google Scholar
• ObaYSarvaSTDiasSEfficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDMunzuCKilbrideSChurchAMagnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trialsRespir Med2016112657426797016
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMMergelVLeselbaumARCaractaCFEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med2014108458459224534204
   PubMed Web of Science ®Google Scholar
• MaltaisFSinghSDonaldACEffects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trialsTher Adv Respir Dis20148616918125452426
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• FramptonJEQVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary diseaseDrugs201474446548824604791
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• MedicGLindnerLvan der WeijdenMKarabisAEfficacy and safety of aclidinium/formoterol versus tiotropium in COPD: results of an indirect treatment comparisonAdv Ther201633337939926883661
   PubMed Web of Science ®Google Scholar
• RodrigoGJPlazaVEfficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic reviewChest2014146230931724556877
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 μg in COPD: a randomized, controlled studyChest2014145598199124385182
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• CazzolaMBeehKMPriceDRocheNAssessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPDPulm Pharmacol Ther201531687825727846
   PubMed Web of Science ®Google Scholar
• SentellasSRamosIAlbertiJAclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolitesEur J Pharm Sci201039528329020093184
   PubMed Web of Science ®Google Scholar
• VestboJLangePPrevention of COPD exacerbations: medications and other controversiesERJ Open Res2015110001127730132
   PubMedGoogle Scholar
• RocheNPribilCVan GanseEReal-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational studyBMC Pulm Med2014145624694050
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
   PubMed Web of Science ®Google Scholar
• LahousseLVerhammeKMStrickerBHBrusselleGGCardiac effects of current treatments of chronic obstructive pulmonary diseaseLancet Respir Med20164214916426794033
   PubMed Web of Science ®Google Scholar
• DecramerMCooperCBTreatment of COPD: the sooner the better?Thorax201065983784120805184
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar